Capture of mesothelioma cells with ‘universal’ CTC-chip

Yoneda,Kazue; Chikaishi,Yasuhiro; Kuwata,Taiji; Ohnaga,Takashi; Tanaka,Fumihiro

doi:10.3892/ol.2017.7619

Capture of mesothelioma cells with ‘universal’ CTC-chip

Authors:
- Kazue Yoneda
- Yasuhiro Chikaishi
- Taiji Kuwata
- Takashi Ohnaga
- Fumihiro Tanaka
View Affiliations

Affiliations: Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan, Central Research Institute, Toyama Industrial Technology Center, Takaoka, Toyama 933‑0981, Japan
Published online on: December 14, 2017 https://doi.org/10.3892/ol.2017.7619
Pages: 2635-2640

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant mesothelioma (MM) is a highly aggressive malignant tumor, predominantly associated with job‑related exposure to asbestos. Development of effective and non‑invasive modalities for diagnosis is an important issue in occupational medicine. Circulating tumor cells (CTCs), which are tumor cells that are shed from primary tumors and circulate in the peripheral blood, may be detected at an earlier stage than malignant tumors, and detection of CTCs may provide a novel insight into the diagnosis of MM. In a previous study evaluating clinical utility of CTCs, detected with a widely used system ‘CellSearch’, the authors indicated a significant however insufficient capability in the diagnosis of MM, suggesting need for a more sensitive system. Accordingly, the authors developed a novel microfluidic system to capture CTCs (CTC‑chip), and demonstrated that the CTC‑chip effectively captured MM cells (ACC‑MESO‑4) spiked in the blood by conjugating an anti‑podoplanin antibody. The results of the present study demonstrated that the CTC‑chip coated with the anti‑podoplanin antibody captured another MM cell (ACC‑MESO‑1). However, the capture efficiencies were lower than those for ACC‑MESO‑4. In addition, an anti‑mesothelin antibody was used to capture CTCs, however the CTC‑chip coated with the anti‑mesothelin antibody failed to effectively capture MM cells, possibly due to low mesothelin expression. Overall, the CTC‑chip may capture specific types of CTCs by conjugating any antibody against an antigen expressed on CTCs, and may be a useful system for the diagnosis of malignant tumors, including MM.

View Figures

View References

1	Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G and Simon GR: Malignant pleural mesothelioma: A comprehensive review. Cancer Control. 13:255–263. 2006. View Article : Google Scholar : PubMed/NCBI
2	Tsiouris A and Walesby RK: Malignant pleural mesothelioma: Current concepts in treatment. Nat Clin Pract Oncol. 4:344–352. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi T, et al: Ecological association between asbestos-related diseases and historical asbestos consumption: An international analysis. Lancet. 369:844–849. 2007. View Article : Google Scholar : PubMed/NCBI
4	Takahashi K and Landrigan PJ: Collequim Ramazzini: The global health dimensions of asbestos and asbestos-related diseases. Ann Glob Health. 82:209–213. 2016. View Article : Google Scholar : PubMed/NCBI
5	Tomasson K, Gudmundsson G, Briem H and Rafnsson V: Malignant mesothelioma incidence by nation-wide cancer registry: A population-based study. J Occup Med Toxicol. 11:372016. View Article : Google Scholar : PubMed/NCBI
6	Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 35:479–495. 2010. View Article : Google Scholar : PubMed/NCBI
7	Stahel RA, Weder W, Lievens Y and Felip E: ESMO Guidelines Working Group: Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl 5:v126–v128. 2010. View Article : Google Scholar : PubMed/NCBI
8	van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA and Moons KG: Markers for the non-invasive diagnosis of mesothelioma: A systematic review. Br J Cancer. 104:1325–1333. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Portal Rodríguez JA, et al: Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J Clin Oncol. 30:1541–1549. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tanaka F, Yoneda K and Hasegawa S: Circulating tumor cell (CTC) in lung cancer: Current status and future perspectives. Lung Cancer (Auckl). 1:77–84. 2010.PubMed/NCBI
11	Tanaka F and Yoneda K: Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today. 46:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
12	Allard WJ, Matera J, Miller MC, Repollet M, Connely MC, Rao C, Tibbe AGJ, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
13	Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, et al: Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM). Ann Surg Oncol. 21 Suppl 4:S472–S480. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ohnaga T, Shimada Y, Moriyama M, Kishi H, Obata T, Takata K, Okumura T, Nagata T, Muraguchi A and Tsukada K: Polymeric microfluidic devices exhibiting sufficient capture of cancer cell line for isolation of circulating tumor cells. Biomed Microdevices. 15:611–616. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chikaishi Y, Yoneda K, Ohnaga T and Tanaka F: EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’. Oncol Rep. 37:77–82. 2017. View Article : Google Scholar : PubMed/NCBI
16	Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y and Hida T: Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
17	Kimura N and Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
18	Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, et al: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol. 190:6239–6249. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 36:372–380. 2005. View Article : Google Scholar : PubMed/NCBI
20	Toss A, Mu Z, Fernandez S and Cristofanilli M: CTC enumeration and characterization: Moving toward personalized medicine. Ann Transl Med. 2:1082014.PubMed/NCBI
21	Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar : PubMed/NCBI
22	Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 133:1317–1331. 2009.PubMed/NCBI
23	Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, et al: An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther. 13:2630–2640. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T and Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 23:1458–1466. 2010. View Article : Google Scholar : PubMed/NCBI